|Mr. Ryan Spencer||CEO & Director||545.59k||N/A||1978|
|Mr. David F. Novack||Pres & COO||697.27k||N/A||1962|
|Mr. Michael S. Ostrach||CFO, Chief Bus. Officer & Sr. VP||662.54k||N/A||1952|
|Dr. Robert Janssen||Chief Medical Officer & Sr. VP of Clinical Devel., Medical and Regulatory Affairs||666.13k||N/A||1954|
|Mr. Justin Burgess||Principal Accounting Officer & Controller||N/A||N/A||N/A|
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older. Its immuno-oncology portfolio includes development stage products, such as SD-101 and DV281. Dynavax Technologies Corporation has a research collaboration with Clover Biopharmaceuticals; the University of Queensland and the Coalition for Epidemic Preparedness; and Sinovac Biotech Ltd. for the development of a vaccine candidate to prevent coronavirus (COVID-19). Dynavax Technologies Corporation has partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to create a vaccine against COVID-19 infection; a collaboration with Valneva SE to initiate a vaccine program for the coronavirus, COVID-19; and collaboration with Medicago to develop a novel adjuvanted COVID 19 vaccine candidate. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Emeryville, California.
Dynavax Technologies Corporation’s ISS Governance QualityScore as of December 9, 2019 is 6. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 8; Compensation: 5.